| News

Rhizen drug secures approval in the USA

10.02.2021

The United States Food and Drug Administration has granted accelerated approval for the drug Umbralisib. Basel biotech Rhizen has discovered this inhibitor for the treatment of cancer.

Swaroop Vakkalanka, President and CEO of Rhizen Pharmaceuticals (img: Rhizen)

Rhizen Pharmaceuticals has discovered Umbralisib, a medication that has now been approved by the US Food and Drug Administration (FDA) for the treatment of patients with certain types of marginal zone lymphoma (MZL) and follicular lymphoma (FL). Rhizen licensed the inhibitor to TG Therapeutics based in the USA, which also did its total clinical development. The Basel biotech has retained commercialization rights for India as well as being the manufacturing and supply partner for Umbralisib, as was reported in a press release.

Umbralisib is an oral, once daily, inhibitor of phosphoinositide 3 kinase delta and casein kinase 1 epsilon. “Umbralisib’s approval offers MZL and FL patients a new treatment option and is a huge validation of Rhizen’s drug discovery & development capabilities,“ said Swaroop Vakkalanka, President & CEO of Rhizen Pharmaceuticals, in the press release.

Rhizen relocated from La Chaux-de-Fonds in the canton of Neuchâtel to Basel in December 2020, with support from Basel Area Business & Innovation, the investment and innovation promotion agency. At the new main location in Basel, the clinical development and commercialization of the novel oncology and inflammation medicines are to be promoted. In particular, Rhizen wants to benefit from the proximity to the Basel Area life sciences cluster. It furthermore plans to grow and create local jobs, so the highly qualified talent offered by Basel was another key factor.

“Basel with its vibrant biotech and pharma ecosystem offers the best opportunity for Rhizen to expand and focus on clinical development of its rich pipeline of investigational drugs,” explained Vakkalanka.

Share this article

Sign up to receive our newsletter in your inbox.

You may also be interested in

Bottmedical enters the market with innovative braces
Basel Area Business & Innovation, Innovation, Invest

Bottmedical enters the market with innovative braces

The Basel-based startup Bottmedical has developed clear braces made from bio-based polymers. After closing a successful financing round, the company...

Read More
TargImmune raises nearly 18 million Swiss francs
Basel Area Business & Innovation, Innovation, Invest

TargImmune raises nearly 18 million Swiss francs

The Basel-based biotechnology firm TargImmune has raised 17.7 million Swiss francs as part of a financing round. It now intends...

Read More
KetoSwiss launches first product in the USA
Basel Area Business & Innovation, Innovation, Invest

KetoSwiss launches first product in the USA

The Basel-based biotech startup KetoSwiss develops innovative therapies for neurological disorders. Following a successful capital increase, the company now has...

Read More
For Swiss startups, China might be closer than it seems
Basel Area Business & Innovation, Invest

For Swiss startups, China might be closer than it seems

China wants to strengthen domestic demand and be less dependent on imports. This policy has huge implications for the life...

Read More
Basel Area treads unique path
Basel Area Business & Innovation, Innovation, Invest

Basel Area treads unique path

Basel Area is responsible for both location and innovation promotion. This approach, which is unique across Switzerland, is very successful...

Read More
Alentis secures 67 million US dollars
Basel Area Business & Innovation, Innovation, Invest

Alentis secures 67 million US dollars

The Basel-based biotechnology company Alentis Therapeutics has secured 67 million US dollars in a series B funding round. The funds...

Read More
1 2 3 46

Do you have a question? We'd like to hear from you.